Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

European growth sends Polynovo (ASX:PNV) shares higher

The Polynovo Ltd (ASX: PNV) share price is up around 7% after announcing European growth.

Polynovo is a business involved in helping regenerating skin that’s been lost through extensive surgery or buns. NovoSorb is a range of bio-resorbable polymers that can be produced in many formats and have unique properties that provide strong biocompatibility, control over physical properties and programmable bio-resorption profile.

European growth

Polynovo has announced its entry into Poland with the appointment of Hortho Medical Innovations as its exclusive distributor.

Hortho distributes devices for medical reconstruction, as well as a number of complimentary bio-absorbable implant technologies and it works closely with key opinion leaders in plastic and reconstruction surgery. Hortho has a direct team servicing all of Poland and plans to add dedicated personal to support their NovoSorb BTM sales and marketing.

Poland is the six largest country in the European Union with a population of more than 38 million, and a medical device market valued at over $2.2 billion.

Polynovo Managing Director Paul Brennan said: “Poland is an exciting growth market in Europe and we see this partnership as an important step in expanding our sales in Europe.”

Turkey

The company also announced it’s entering the Turkish market with the appointment of Incomed Saglik Hiz and its medical sales channel LotuS as the distributor.

Polynovo said this was a significant step in expanding to a significant number of surgeons and patients in the region.

LotuS has an established product portfolio and sales relationships within wound and burn treatment.

Polynovo said that Turkey has seen significant economic growth over the past 10 years, and it is building a modern medical industry. Turkey has a population of 82 million people and a GDP of US$761 billion in 2019. Polynovo sees good medium term opportunities in Turkey.

Polynovo Managing Director Paul Brennan said: “We are excited by our partnership with LotuS mcd and our entry into Turkey. The country is an important geographical and commercial link in our European, Mediterranean and Middle East strategy. We will now be able to service surgeons who work across EMEA and expand the inter-surgeon referral of the benefits of NovoSorb BTM.”

Summary thoughts

Polynovo continues to expand and it could be worth a small buy today if you believe in its growth story. The Polynovo share price has dropped heavily since early January.

However, there are other ASX growth shares that I understand better like Pushpay Holdings Ltd (ASX: PPH) and VanEck Vectors Video Gaming and eSports ETF (ASX: ESPO) which I think could be better value.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content